Related Experiment Video
Updated: Jun 23, 2026
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
Published on: January 6, 2012
Effects of STAT Inhibitors in Mouse Models of Endometriosis
Hiroaki Inui1, Takako Kawakita2, Misaki Murayama1
1Department of Obstetrics and Gynecology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima City, Tokushima, Japan.
Abstract:
The signal transducer and activator of transcription (STAT) pathway, which regulates cell proliferation and immunity, has been implicated in chronic inflammatory diseases such as rheumatoid arthritis. However, few reports have described the effects of STAT inhibitors on endometriosis, another chronic inflammatory disease. Here, we investigated the intraperitoneal microenvironment and the effects of a STAT inhibitor in a mouse model of endometriosis. In the treatment group, a STAT3 inhibitor (Stattic®, 80 mg/kg) was orally administered three times per week; control animals received orally dosed phosphate-buffered saline. Endometriosis-like lesions and peritoneal lavage fluid were collected before and 1, 2, and 3 weeks after STAT3 inhibitor administration was initiated. The lesion area was significantly increased in both groups after the first week. However, in the treatment group, the lesion areas were significantly reduced at weeks 2 and 3 compared with week 1. Transforming growth factor (TGF)-β messenger RNA (mRNA) levels in ascites cells were significantly lower at weeks 1 and 2 than at week 0. Interleukin (IL)-6 mRNA levels were significantly higher at week 1 than at week 0 but were significantly lower at weeks 2 and 3 than at week 1. Thus, STAT inhibitors appeared to reduce the extent of endometriosis in this mouse model, and may also inhibit the IL-6 signaling pathway and reduce TGF-β levels. This study suggests that STAT inhibitors warrant further exploration for use in the treatment of endometriosis.
Insights
STAT inhibitors show promise for treating endometriosis, a chronic inflammatory disease. This study found that a STAT3 inhibitor reduced lesion size and altered inflammatory markers in a mouse model.
Area of Science:
- Reproductive biology
- Immunology
- Pharmacology
Background:
- The signal transducer and activator of transcription (STAT) pathway is crucial for cell proliferation and immunity.
- STAT pathway dysregulation is linked to chronic inflammatory conditions like rheumatoid arthritis.
- Limited research exists on STAT inhibitors' effects on endometriosis, another chronic inflammatory disease.
Purpose of the Study:
- To investigate the impact of a STAT3 inhibitor on the intraperitoneal microenvironment in a mouse model of endometriosis.
- To evaluate the therapeutic potential of STAT inhibitors for endometriosis treatment.
Main Methods:
- A mouse model of endometriosis was established.
- Animals received either a STAT3 inhibitor (Stattic®, 80 mg/kg) or phosphate-buffered saline orally, three times weekly.
- Endometriotic lesion area and peritoneal lavage fluid were analyzed at baseline and weeks 1, 2, and 3 post-treatment.
Main Results:
- Lesion area initially increased in both groups but significantly decreased in the treatment group at weeks 2 and 3.
- Transforming growth factor-beta (TGF-β) mRNA levels in ascites cells were reduced at weeks 1 and 2.
- Interleukin-6 (IL-6) mRNA levels initially increased then decreased in the treatment group, suggesting STAT inhibitor effects on IL-6 signaling.
Conclusions:
- STAT inhibitors demonstrated a potential to reduce endometriosis extent in a preclinical mouse model.
- The findings suggest STAT inhibitors may modulate IL-6 and TGF-β pathways relevant to endometriosis.
- STAT inhibitors warrant further investigation as a therapeutic strategy for endometriosis.
